CoChat

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Open access

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.

Abstract

Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients. This work was undertaken to better understand the effect of metformin use on liver cancer risk in diabetic patients.A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, and Cochrane Library through July 30, 2016. Meta-analyses were performed using Stata version 12.0, with odds ratio (ORs) and 95% confidence intervals (CIs) as effect measures.Twenty-three studies were included. Meta-analysis of 19 studies involving 550,882 diabetic subjects suggested that metformin use reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40-0.68) compared with nonusers. The protective effect was validated in all the exploratory subgroup analyses, except that pooled result of post hoc analyses of 2 randomized controlled trials found no significant difference between subjects with metformin and those without, with OR being 0.84 (95% CI, 0.10-6.83). After adjusting for hepatitis B/C virus infection, cirrhosis, obesity, behavioral factors, and time-related bias, the association was stable, pooled OR ranged from 0.42 to 0.75.A protective effect for liver cancer was found in diabetic metformin users. However, more randomized clinical evidence is still needed to verify the results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000006888

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram of study selection. RCT = randomized controlled trials.
Figure 1 PRISMA flow diagram of study selection. RCT = randomized controlled trials.CC BY · PubMed Central
Figure 2 Forest plot of the association between use of metformin and liver cancer risk in diabetic patients. RCT = randomized controlled trials. ∗Studies were multiple publications and they were only included in corresponding subgroup analysis.
Figure 2 Forest plot of the association between use of metformin and liver cancer risk in diabetic patients. RCT = randomized controlled trials. ∗Studies were multiple publications and they were only included in corresponding subgroup analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 2

  1. Aydin, 2013, Oral antidiabetics and insulins do not increase cancer risk, Acta Medica Mediterr, 29, 859
  2. Zheng, 2012, Metformin inhibits proliferation and colony formation ability through AMP-activated protein kinase in hepatocellular carcinoma cells, Diabetes, 61, A457

Cited by

See all 91

Metadata

Authors
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H.
Affiliations
Central South University (CN)
Corresponding author
Tan, Hongzhuan
Venue
Medicine
Published
2017-05
Volume
96
Issue
19
Pages
e6888
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2613565875
Cited by
89
References
59
Citations by year
2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 16 · 2021: 15 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 3
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
metformin, liver cancer, hepatocellular carcinoma, diabetes mellitus, chemoprevention, cancer risk reduction, hepatocellular carcinoma incidence
MeSH terms
Animals, Diabetes Mellitus, Humans, Hypoglycemic Agents, Liver Neoplasms, Metformin, Risk, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. https://app.cochat.ai/papers/10.1097/md.0000000000006888
The paper
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017). Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine. https://doi.org/10.1097/md.0000000000006888

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.